U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07459647) titled 'A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia' on March 05.
Brief Summary: ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: ML-007C-MA
ML-007C-MA dosed as 210/3 mg BID
Recruitment Status: NOT_YET_RECRUITING
Sponsor: MapLight Therapeutics
Published by HT Digital Content Services ...